EntryPoint Capital LLC Has $483,000 Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

EntryPoint Capital LLC grew its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 475.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 135,797 shares of the company’s stock after purchasing an additional 112,210 shares during the quarter. EntryPoint Capital LLC’s holdings in Aquestive Therapeutics were worth $483,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. New York State Common Retirement Fund lifted its position in Aquestive Therapeutics by 713.3% during the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after buying an additional 10,700 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Aquestive Therapeutics in the third quarter worth about $90,000. BNP Paribas Financial Markets lifted its position in shares of Aquestive Therapeutics by 252.2% during the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after purchasing an additional 13,481 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aquestive Therapeutics during the fourth quarter valued at approximately $69,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Aquestive Therapeutics in the third quarter valued at approximately $135,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST opened at $3.22 on Wednesday. The company has a 50 day moving average price of $2.99 and a two-hundred day moving average price of $3.98. The company has a market capitalization of $318.36 million, a PE ratio of -7.16 and a beta of 2.76. Aquestive Therapeutics, Inc. has a 52 week low of $2.24 and a 52 week high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The company had revenue of $11.87 million for the quarter, compared to analyst estimates of $13.11 million. On average, sell-side analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analyst Weigh In

AQST has been the topic of a number of recent research reports. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a research report on Friday, March 7th. Alliance Global Partners reiterated a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Cantor Fitzgerald began coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Monday, March 10th. Finally, Lake Street Capital dropped their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $10.57.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.